Literature DB >> 10772605

Use of antiretroviral therapies by HIV-infected persons receiving methadone maintenance.

M D Stein1, M E Urdaneta, J Clarke, J Maksad, M Sobota, L Hanna, L E Markson.   

Abstract

HIV-infected persons receiving methadone maintenance must often seek their medical care at a separate site. However, little data is available on the receipt of antiretroviral therapy (ART), beliefs about ART, and influences on the decision to initiate ART among those referred off-site. HIV-infected injection drug users (n = 72) were interviewed at three methadone maintenance programs; 83% with CD4 cell counts under 500 reported that they had received ART. Of these persons, 56% had used three drug combination therapy. Beliefs about the benefits of ART included: increased survival, 96%; decreased viral load 87%; decreased HIV-related infections 87%; could cure HIV, 29%. For those receiving ART, physician input, CD4 count, and possible side effects were more important than friends, family or mass media in deciding to start ART. We conclude that the model of referral for HIV care off-site does not appear to impede access to ART for HIV-infected IDUs in methadone maintenance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10772605     DOI: 10.1300/J069v19n01_07

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  3 in total

1.  Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy.

Authors:  Anita Palepu; Mark W Tyndall; Kathy Li; Benita Yip; Michael V O'Shaughnessy; Martin T Schechter; Julio S G Montaner; Robert S Hogg
Journal:  J Urban Health       Date:  2003-12       Impact factor: 3.671

2.  Optimising treatment in opioid dependency in primary care: results from a national key stakeholder and expert focus group in Ireland.

Authors:  Marie Claire Van Hout; Des Crowley; Aoife McBride; Ide Delargy
Journal:  BMC Fam Pract       Date:  2018-06-30       Impact factor: 2.497

Review 3.  Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions.

Authors:  Sauzanne Khalilieh; Ka Lai Yee; Rosa Sanchez; S Aubrey Stoch; Larissa Wenning; Marian Iwamoto
Journal:  Clin Drug Investig       Date:  2020-10       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.